Park Ha Biological Technology Co., Ltd. (PHH)

PHH Income Statement

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021
Revenue	2.77	2.38	2.46	1.92	0.93
Revenue Growth (YoY)	42.65%	-3.14%	28.12%	106.16%	-
Cost of Revenue	0.16	0.2	0.31	0.51	0.31
Gross Profit	2.61	2.19	2.15	1.41	0.62
Selling, General & Admin	21.43	1.18	0.78	1.15	1.12
Research & Development	0.04	0.04	0.03	0.06	-
Operating Expenses	21.63	1.39	0.97	1.21	1.12
Operating Income	-19.01	0.79	1.18	0.2	-0.5
Interest Expense	-0	-	-	-0	-0
Interest & Investment Income	0	0	0	0	0
Other Non Operating Income (Expenses)	0.06	-0	-0	-0.01	0.02
Pretax Income	-18.96	0.79	1.18	0.19	-0.48
Income Tax Expense	0.45	0.31	0.33	-0	-
Net Income	-19.41	0.48	0.85	0.19	-0.48
Net Income to Common	-19.41	0.48	0.85	0.19	-0.48
Net Income Growth	-	-43.83%	345.40%	-	-
Shares Outstanding (Basic)	26	25	25	25	25
Shares Outstanding (Diluted)	26	25	25	25	25
EPS (Basic)	-0.75	0.02	0.03	0.01	-0.02
EPS (Diluted)	-0.75	0.02	0.03	0.01	-0.02
EPS Growth	-	-43.83%	345.44%	-	-
Free Cash Flow	1.09	0.87	0.1	1.43	-0.51
Free Cash Flow Per Share	0.04	0.04	0.00	0.06	-0.02
Gross Margin	94.37%	91.80%	87.35%	73.47%	66.58%
Operating Margin	-686.90%	33.32%	48.01%	10.27%	-53.81%
Profit Margin	-701.07%	20.09%	34.65%	9.97%	-52.09%
Free Cash Flow Margin	39.34%	36.73%	4.22%	74.52%	-54.86%
EBITDA	-18.99	0.82	1.2	0.23	-0.46
EBITDA Margin	-	34.28%	48.82%	11.85%	-49.62%
D&A For EBITDA	0.03	0.02	0.02	0.03	0.04
EBIT	-19.01	0.79	1.18	0.2	-0.5
EBIT Margin	-	33.32%	48.01%	10.27%	-53.81%
Effective Tax Rate	-	39.68%	27.89%	-	-
Advertising Expenses	-	0	0	-	0.04

Updated Feb 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q